Making decisions about hormone replacement therapy

British Medical Journal

Volumn 326, Issue 7384, 2003, Pages 322-326

  Rymer, Janice ^a   Wilson, Ruth ^b   Ballard, Karen ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b QUEEN S UNIVERSITY   (Canada)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE;

BREAST CANCER; CARDIOVASCULAR RISK; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; MEDICAL DECISION MAKING; OSTEOPOROSIS; OVARY CANCER; PATIENT COUNSELING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; TREATMENT INDICATION; VEIN THROMBOSIS;

EID: 0037425829     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.326.7384.322     Document Type: Review

References (34)

1. Ballard K. Women's use of hormone replacement therapy for disease prevention: results of a community survey. Br J Gen. Pract 2002;52:835-7.
2. Kuh DJ, Wadsworth MEJ, Hardy R. Women's health in midlife: the influence of the menopause, social factors and health in earlier life. Br J Obstet Gynaecol 1997;104:923-33.
3. Fletcher SW, Colditz G. Failure of oestrogen plus progestin therapy for prevention. JAMA 2002;288:366-8.
4. Griffiths F. Women's control and choice regarding HRT. Soc Sci Med 1999;49:469-81.
5. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
6. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestorone in healthy post-menopausal women. JAMA 2002;288:321-33.
7. Gold EB, Sternfeld B, Kelsy JL, Brown C, Mouton C, Reame N, et al. The relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152:463-73.
8. Avis NE, Stellato R, Crawford S, Bromberger J, Ganz P, Cain V, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001;52:345-56.
9. Lock M. Encounters with ageing: mythologies of menopause in Japan and North America. Berkeley: University of California Press, 1994.
10. Hunter MS, O'Dea I, Britten N. Decision-making and hormone replacement therapy: a qualitative analysis. Soc Sci Med 1997;45:1541-8.
11. Porter M, Penney GC, Russell D, Russell E, Templeton A. A population based survey of women's experience of the menopause. Br J Obstet Gynaecol 1996;103:1025-8.
12. Kuh DJ, Hardy R, Wandsworth MEJ. Social and behavioural influences on the uptake of hormone replacement therapy among younger women. Br J Obstet Gynaecol 2000;107:731-9.
13. Abraham S, Perz J, Clarkson R, Llewellyn-Jones D. Australian women's perceptions of hormone replacement therapy over 10 years. Maturitas 1995;21:91-5.
14. Rymer J, Morris EP. Extracts from Clinical Evidence: menopausal symptoms. BMJ 2002;321:1516-9.
15. Eriksen PS, Rasmussen H. Low dose 17β oestradiol vaginal tablets in the treatment of atrophic vaginities: a double blind placebo controlled study. Eur J Obstet Gynaecol Reprod Biol 1992;44:137-44.
16. Zethraeus N, Johannesson M, Henricksson P, Strand RT. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol 1999;104:1191-5.
17. Cooper C. Epidemiology and definition of osteoporosis. In: Compston JE, ed. Osteoporosis: new perspectives on causes, prevention and treatment. London: Royal College of Physicians, 1996:1-10.
18. Torgerson DJ, Bell-Syer SE. Hormone replacernent therapy and prevention of non-vertebral fractures: a meta-analysis of randomised trials. JAMA 2001;285:2891-7.
19. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210.
20. Grady D, Gebretsadick T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynaecol 1995;85:304-13.
21. Hulley S, Furberg C, Barret-Connore C, Cauley J, Grady D, Haskell W, et al. Non-cardiovascular disease outcomes during 6.8 years on hormone therapy: heart and estrogen/progestin replacement study follow up (HERS II). JAMA 2002;288:58-66.
22. Grady D, Herrington D, Bittner V, Davidson M, Hlatky M, Hsia J, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288:49-57.
23. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of HRT. Lancet 1996;348:977-80.
24. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-3.
25. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, et al. Postmenopausal hormone replacement therapy increases risk for venous thromboembolism disease: the heart and estrogen/progestin replacement study. Ann Intern Med 2000;132:689-96.
26. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574-82.
27. Hunter MS, O'Dea I. Perception of future health risks in mid-aged women: estimates with and without, behavioural changes and hormone replacement therapy. Maturitas 1999;33:37-43.
28. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
29. Beresford S, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349:458-61.
30. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7.
31. Sturdee DW, Ulrich LG, Barlow DH, Wells M, Campbell MJ, Vessey MP, et al. The endometrial response to sequential and continuous combined oestrogen/progestogen replacement therapy. Br J Obstet Gynaecol 2000;107:1392-400.
32. Wells M, Sturdee D, Barlow DH, Ulrich LG, O'Brien K, Campbell MJ, et al. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study. BMJ 2002;325:239.
33. Lacey, JV, Mink, PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-41.
34. Raudaskoski T, Tapanainen J, Tomas E, Luotdo H, Pekonen F Ronni Sivula H, et al. Intrauterine 10 microgm and 20 microgm levonorgestrel systems in postmenopausal women receiving oral oestrogen therapy: clinical, endometrial and metabolic response. Br J Obstet Gynaecol 2002;109:136-44.